Change is the 2026-10-09 close against the previous close; the industry change is the equal-weighted average of its stocks. Sub-industry classification is maintained by cibo. Last FY is each company's latest annual report. Net profit is profit attributable to owners of the parent; ROE = net profit / closing equity attributable to owners. Non-HKD statements are converted at ECB reference rates.
Management
NamePosition
SLShanghai Fosun Pharmaceutical (Group) Co., Ltd.Executive Director
陈陈玉卿Executive Director
关关晓晖Executive Director
文文德镛Executive Director
王王可心Executive Director
刘刘毅Executive Director
陈陈启宇Non-Executive Director
潘潘东辉Non-Executive Director
余余梓山Independent Non-Executive Director
王王全弟Independent Non-Executive Director
CPChen Penghui Independent Non-Executive Director
杨杨玉成Independent Non-Executive Director
严严佳Independent Non-Executive Director
Board list from the HKEXnews "List of Directors and their Role and Function", as of 2025-12-02.
About this page
This page shows FOSUN PHARMA (02196) company information, related securities, the price change distribution and in-industry rankings within its sub-industry, and the board of directors. Quotes come from HKEX Daily Quotations, financial metrics from each company's latest annual report, and the director list from HKEXnews.